KEAP1 and lung carcinoma: As discussed above, KEAP1 promoter methylation was first reported in lung cancer, but similar observations have been linked to poor prognosis in glioma, breast cancer, non-small cell lung carcinoma, colorectal cancer, clear renal cell carcinoma, and pancreatic cancer [33,34,35,36,37,38].